![cagrilintide phase 2 In the REDEFINE 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results PDF] Safety, tolerability, pharmacokinetics, and](https://lookaside.fbsbx.com/lookaside/crawler/threads/DNiZi_aqf_e/0/image.jpg)
cagrilintide phase 2
Shipping Estimate
cagrilintide phase 2 In the REDEFINE 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results PDF] Safety, tolerability, pharmacokinetics, and
EUR25.01
EUR54.01
Pay in 4 interest-free payments of $6.25 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
![cagrilintide phase 2 In the REDEFINE 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results PDF] Safety, tolerability, pharmacokinetics, and](https://figures.semanticscholar.org/e338e8f8bf819030be1ae81167c7d20946acbbb5/7-Table2-1.png)
![cagrilintide phase 2 In the REDEFINE 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results PDF] Safety, tolerability, pharmacokinetics, and](https://pbs.twimg.com/media/GygIanPaMAAjkf_.png)
![cagrilintide phase 2 In the REDEFINE 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results PDF] Safety, tolerability, pharmacokinetics, and](https://www.thelancet.com/cms/10.1016/S0140-6736(23)01163-7/asset/574129d4-809d-4296-9b7e-10d493ffcfad/main.assets/gr1_lrg.jpg)
![cagrilintide phase 2 In the REDEFINE 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results PDF] Safety, tolerability, pharmacokinetics, and](https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?cid=171397054&t=l)
